These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
241 related items for PubMed ID: 12512383
1. Inhibitors of the ras oncogene as therapeutic targets. Ghobrial IM, Adjei AA. Hematol Oncol Clin North Am; 2002 Oct; 16(5):1065-88. PubMed ID: 12512383 [Abstract] [Full Text] [Related]
6. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. Caponigro F. Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276 [Abstract] [Full Text] [Related]
7. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Sebti SM, Hamilton AD. Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643 [Abstract] [Full Text] [Related]
8. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM. Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225 [Abstract] [Full Text] [Related]
9. Re: Blocking oncogenic Ras signaling for cancer therapy. Canevari S, Biocca S, Figini M. J Natl Cancer Inst; 2002 Jul 03; 94(13):1031-2; author reply 1032. PubMed ID: 12096090 [No Abstract] [Full Text] [Related]
11. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Morgan MA, Ganser A, Reuter CW. Leukemia; 2003 Aug 03; 17(8):1482-98. PubMed ID: 12886235 [Abstract] [Full Text] [Related]
13. Perspectives on farnesyl transferase inhibitors in cancer therapy. Mazieres J, Pradines A, Favre G. Cancer Lett; 2004 Apr 08; 206(2):159-67. PubMed ID: 15013521 [Abstract] [Full Text] [Related]